Asl Elmira Roshani, Rasmi Yousef, Khadem-Ansari Mohammad-Hasan, Seyed-Mohammadzad MirHossein, Rostamzadeh Alireza, Ghaffari Fereshteh, Mokarizadeh Narmin
Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran.
Med Pharm Rep. 2019 Jan;92(1):31-35. doi: 10.15386/cjmed-1101. Epub 2019 Jan 15.
Recent studies have suggested that angiogenic factors may affect vascular endothelial integrity. On the other hand, endothelial dysfunction is the main pathological mechanism in microvascular angina (MVA) or cardiac syndrome X. Therefore, we aimed to determine the levels of angiogenic factors in MVA patients. In addition, we investigated the effects of metoprolol, as a beta blocker agent, on the serum levels of these factors.
Thirty patients with MVA (17 female/13 male; mean age: 55.53±9.18 years) and twenty healthy controls (14 female/6 male; mean age: 51.40±9.16 years) were enrolled.The serum amounts of angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2) and tyrosine kinase-2 receptor (Tie-2) were measured in healthy controls, MVA patients at baseline and after metoprolol therapy (25 mg for one month) by enzyme-linked immunosorbent assay.
The levels of Ang-2 and Tie-2 were significantly higher in MVA patients at baseline in comparison with controls (Ang-2: 277.02±186.08 vs.164.46±49.83 ng/l, P=0.011; Tie-2: 28.97±18.85 vs. 14.90±4.05 ng/ml, P=0.002; respectively). But this difference in the Ang-1 levels was not significant (P=0.829). Additionally, the levels of angiogenic factors in MVA patients after metoprolol therapy were not significantly changed in comparison with the baseline status (P>0.05).
Our results considered a possible role for angiogenic factors in the pathophysiology of MVA, which need further investigation for elucidation. In addition, this study has not showed an effective role for metoprolol in changing the angiogenic factors levels as a therapeutic agent in MVA.
近期研究表明血管生成因子可能影响血管内皮完整性。另一方面，内皮功能障碍是微血管性心绞痛（MVA）或心脏综合征X的主要病理机制。因此，我们旨在测定MVA患者血管生成因子的水平。此外，我们研究了作为β受体阻滞剂的美托洛尔对这些因子血清水平的影响。
纳入30例MVA患者（17例女性/13例男性；平均年龄：55.53±9.18岁）和20例健康对照者（14例女性/6例男性；平均年龄：51.40±9.16岁）。通过酶联免疫吸附测定法测量健康对照者、MVA患者基线时以及美托洛尔治疗（25mg，持续1个月）后的血清血管生成素-1（Ang-1）、血管生成素-2（Ang-2）和酪氨酸激酶-2受体（Tie-2）的含量。
与对照组相比，MVA患者基线时Ang-2和Tie-2水平显著更高（Ang-2：277.02±186.08 vs.164.46±49.83 ng/l，P = 0.011；Tie-2：28.97±18.85 vs. 14.90±4.05 ng/ml，P = 0.002）。但Ang-1水平的差异不显著（P = 0.829）。此外，与基线状态相比，美托洛尔治疗后MVA患者血管生成因子水平无显著变化（P>0.05）。
我们的结果认为血管生成因子在MVA病理生理学中可能起作用，这需要进一步研究以阐明。此外，本研究未显示美托洛尔作为MVA治疗药物在改变血管生成因子水平方面的有效作用。
